Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmacogenomics (London)

• Publication date

  2016-09-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/PGS-2016-0102PMID 27636246
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• X‐ray repair cross‐complementing 1 polymorphism and prognosis of platinum‐based chemotherapy in gastric and colorectal cancer: A meta‐analysis

  2014cited by this paper
• The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.

  2014cited by this paper
• XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis

  2013cited by this paper
• Assessing Bias in Studies of Prognostic Factors

  2013cited by this paper
• ERCC1 and XPD/ERCC2 Polymorphisms’ Predictive Value of Oxaliplatin‐Based Chemotherapies in Advanced Colorectal Cancer has an Ethnic Discrepancy: A Meta‐analysis

  2012cited by this paper
• Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.

  2012cited by this paper
• Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).

  2011cited by this paper
• ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

  2011cited by this paper
• Pharmacogenetics in colorectal cancer: a systematic review.

  2008cited by this paper
• Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?

  2006cited by this paper
• Systemic therapy for metastatic colorectal cancer: current options, current evidence.

  2005cited by this paper
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.

  2004cited by this paper
• From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity.

  2003cited by this paper
• Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.

  2002cited by this paper
• A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

  2001cited by this paper
• Oxaliplatin-induced damage of cellular DNA.

  2000cited by this paper
• XPD polymorphisms: effects on DNA repair proficiency.

  2000cited by this paper
• Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

  2000cited by this paper
• Clinical pharmacokinetics of oxaliplatin: a critical review.

  2000cited by this paper
• Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution.

  1998cited by this paper
• Drug Development in Contemporary Oncology Methods of Study Selection

  year unknowncited by this paper

• A Case Study on Complete Pathological Response in Advanced Rectal Cancer Patient with Oxaliplatin-based Chemotherapy without Cumulative Neurotoxicity

  2025cites this paper
• GSTM1 and GSTP1 Polymorphisms Affect Outcome in Colorectal Adenocarcinoma

  2024cites this paper
• Pharmacogenetic markers of toxicity of FOLFOX/XELOX chemotherapy in patients with gastrointestinal tumors: a prospective observational study

  2023cites this paper
• Interethnic differences in drug response: projected impact of genetic variations in the Saudi population.

  2023cites this paper
• Predictive “omic” biomarkers of drug response: Colorectal cancer as a model

  2022cites this paper
• Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers

  2022influential citation
• Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines

  2021cites this paper
• Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines

  2021cites this paper
• Genetic Polymorphisms in NAT1, NAT2, GSTM1, GSTP1 and GSTT1 and Susceptibility to Colorectal Cancer among Filipinos

  2020cites this paper
• Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms

  2020cites this paper
• Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review

  2020cites this paper
• Association of DNA repair gene polymorphisms with colorectal cancer risk and treatment outcomes.

  2019cites this paper
• The multi-factorial nature of clinical multidrug resistance in cancer.

  2019cites this paper
• Precision treatment in colorectal cancer: Now and the future

  2019cites this paper
• Biological and predictive role of ERCC1 polymorphisms in cancer.

  2017cites this paper
• Genetic determinants for chemo- and radiotherapy resistance in bladder cancer

  2017cites this paper